



# Oregon Prescription Drug Affordability Board

350 Winter Street NE, Salem, OR 97309-0405 | 971-374-3724 | [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) | [dfr.oregon.gov/pdab](http://dfr.oregon.gov/pdab)

## Agenda

This is a regular meeting. *Date:* **February 21, 2024** | *Time:* **9:30 a.m.**

**This is a draft agenda and subject to change.**

<b>Meeting name</b>	<b>Prescription Drug Affordability Board</b>	<b>Board Members:</b> Akil Patterson; Vice Chair Shelley Bailey; Daniel Hartung; Amy Burns; Robert Judge; John Murray  <b>Staff:</b> Ralph Magrish, executive director; Cortnee Whitlock, policy analyst; Stephen Kooyman, project manager; Brekke Berg, policy analyst, Taran Heins, research analyst, Melissa Stiles, administrative specialist; Jake Gill, counsel; Pramela Reddi, counsel
<b>Meeting location</b>	Virtual	
<b>Zoom link</b>	<a href="#">Register for the meeting</a>	

Purpose	Subject	Presenter	Estimated Time Allotted
<i>Informational and vote</i>	Appointment of interim chair for today's meeting	Ralph Magrish	5 minutes
<i>Informational and vote</i>	Call to order, roll call, approval of <a href="#">1/26/2024 minutes</a>	Interim Chair	5 minutes
<i>Informational</i>	Executive director's program update	Ralph Magrish	5 minutes
<i>Discussion and vote</i>	<b>Affordability review: 1) Ozempic and 2) Trulicity:</b> <ul style="list-style-type: none"> <li>• Drug-specific public comments</li> <li>• Board discussion, including any board questions regarding drug-specific public comments</li> <li>• Potential motion to include products on the list of prescription drugs that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon.</li> </ul>	Ralph Magrish and Cortnee Whitlock	80 minutes ■ Includes 40 minutes for public comment
	Break		5 minutes

### Affordability review: 3) Shingrix:

<i>Discussion and vote</i>	<ul style="list-style-type: none"><li>• Drug-specific public comments</li><li>• Board discussion, including any board questions regarding drug-specific public comments</li><li>• Potential motion to include product on the list of prescription drugs that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon.</li></ul>	Ralph Magrish and Cortnee Whitlock	40 minutes ▪ Includes 20 minutes for public comment
<i>Informational and vote</i>	Election of officer(s)	Interim Chair	3 minutes
<i>Informational</i>	General public comment	Interim Chair	5 minutes
<i>Informational</i>	Adjournment	Interim Chair	2 minutes

## Next meeting

March 20, 2024, at 9:30 a.m.

## Accessibility

Anyone needing assistance due to a disability can contact Melissa Stiles at least 48 hours ahead of the meeting at [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) or 971-374-3724.

## How to submit public comment

### Oral testimony

For oral comments, please submit the PDAB public comment form no later than 24 hours before the PDAB meeting. The form is located on the Prescription Drug Affordability Board [public comment page](#).

### General written testimony

For written comments, please submit the PDAB public comment form with attachments no later than 72 hours before the PDAB meeting. The form is located on the Prescription Drug Affordability Board [public comment page](#). Written comments will be posted to the PDAB website.

### Public comment for drug affordability review

For written comments specific to drugs under review by the board, please submit the PDAB public comment form with attachments by the deadline listed on the [public comment page](#). For oral testimony about drugs under review by the board, please submit the PDAB public comment form no later than 24 hours before the PDAB meeting. The form is located on the Prescription Drug Affordability Board [public comment page](#). Written comments received by the deadline will be included in the board meeting materials and posted to the web.

## Open and closed sessions

All board meetings except executive sessions are open to the public. Pursuant to ORS 192.660, executive sessions are closed, with the exception of news media and staff. No final actions will be taken in the executive session. When action is necessary, the board will return to an open session.